CVS shareholders seek cosmetics safety
This article was originally published in The Rose Sheet
Executive Summary
Reformulation of CVS private label cosmetic products to exclude "chemicals linked to cancer, mutations or birth defects" and review of "product ingredients for suspected carcinogens, mutagens, and reproductive toxins, and for chemicals that affect the endocrine system, accumulate in the body or persist in the environment" are among requests in shareholder resolution to be voted on during May 11 CVS Corp. annual meeting, according to Boston Common Asset Management, a primary filer of the document. Resolution also proposes CVS "proactively seek safe alternatives" for potentially unsafe chemicals and "encourage manufacturers or distributors of cosmetics products sold in CVS to do the same"...